Harbour Biomed

102 articles about Harbour Biomed

• Harbour BioMed Reports Full Year 2023 Financial Results

  3/28/2024

  Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual financial results of full year 2023.

• Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

  1/24/2024

  Harbour BioMed announced that the Company has been granted the clearance of Investigational New Drug from the Food and Drug Administration of the United States to initiate the first-in-human clinical trial in the U.S. for bispecific antibody HBM9027.

• Harbour BioMed Announces Positive Profit Alert

  1/19/2024

  Harbour BioMed announces a positive profit alert for the year ended December 31, 2023.

• Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

  8/28/2023

  Harbour BioMed announced that the U.S. Food and Drug Administration has cleared the investigational new drug application to commence clinical trials of its first antibody drug conjugate program HBM9033.

• Harbour BioMed Announces 2023 Interim Results

  8/28/2023

  Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced its interim results for the six months ended June 30, 2023.

• Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

  8/8/2023

  Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology announced the appointment of Dr. Albert R. Collinson as independent non-executive director.

• Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

  7/13/2023

  Harbour BioMed announces that, it is anticipated that the Company will record a significant increase in its revenue for the six months ended June 30, 2023, leading to profitable results and notable achievements in cost reduction and efficiency improvement.

• Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

  6/29/2023

  Harbour BioMed announces that the National Medical Products Administration (NMPA) of China has accepted the Biologics License Application (BLA) of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG).

• Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

  6/5/2023

  Harbour BioMed announced that the first patient has been dosed in its ongoing phase I trial of the first-in-class anti-B7H7 antibody HBM1020 in the United States.

• Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

  5/29/2023

  Harbour BioMed announced the results of phase Ib clinical trial of porustobart, in combination of toripalimab in patients with hepatocellular carcinoma were released at the American Society of Clinical Oncology Annual Meeting 2023.

• Harbour BioMed Reports Full Year 2022 Financial Results

  4/3/2023

  Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2022.

• Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

  3/6/2023

  Harbour BioMed announces the positive topline results of its phase III clinical trial of batoclimab for the treatment of generalized myasthenia gravis, which is also the first positive pivotal trial outcome for batoclimab worldwide.

• HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

  3/6/2023

  HanAll Biopharma Co., Ltd. (KRX: 009420. KS) announced that its licensed partner Harbour BioMed in Greater China reported positive top-line results from its pivotal Phase 3 clinical trial of batoclimab in generalized myasthenia gravis (gMG) patients.

• Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

  2/14/2023

  Cullinan Oncology, Inc. and Harbour BioMed announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 in the U.S.

• HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

  1/26/2023

  HBM Alpha Therapeutics, Inc. announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hyperplasia and polycystic ovary syndrome, with the lead candidate currently in IND-enabling stage.

• Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 Antibody by the U.S. FDA

  1/12/2023

  Harbour BioMed (the"Company", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its globally first-in-class fully human monoclonal antibody HBM1020 targeting B7H7 (also known as HHLA2) in the U.S.

• Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

  10/20/2022

  Harbour BioMed announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States.

• Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

  9/27/2022

  Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378.

• Harbour BioMed Announces 2022 Interim Results

  8/31/2022

  Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), today announced its interim results for the six months ended June 30, 2022.

• Harbour BioMed to Announce 2022 Interim Results on August 31, 2022

  8/9/2022

  Harbour BioMed announced that it will report financial results for the first half year ended June 30, 2022, on Wednesday, August 31, 2022.